Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Free Report) was the recipient of a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 2,800,000 shares, a growth of 6.5% from the July 15th total of 2,630,000 shares. Approximately 7.0% of the company’s stock are short […]
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Rating)’s share price traded down 1.2% during trading on Tuesday . The company traded as low as $6.77 and last traded at $6.77. 165,730 shares changed hands during trading, a decline of 5% from the average session volume of 173,559 shares. The stock had previously closed at $6.85. […]
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE – Get Rating) was the target of a large drop in short interest in the month of April. As of April 30th, there was short interest totalling 2,240,000 shares, a drop of 10.0% from the April 15th total of 2,490,000 shares. Currently, 5.6% of the company’s stock are short sold. […]
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) is one of 279 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its competitors? We will compare Monte Rosa Therapeutics to related companies based on the strength of its risk, dividends, valuation, analyst recommendations, institutional ownership, profitability and earnings. Analyst Recommendations […]
Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) is one of 279 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Monte Rosa Therapeutics to related companies based on the strength of its risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation. Analyst Recommendations […]